OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBluecross IdahoPolicy MP 5.01.529

Intravenous Monoclonal Antibody Therapy for Migraine Headache

Customize your policy alerts

Sign up for Bluecross Idaho Policy MP 5.01.529 alerts

Get alerted when Policy MP 5.01.529 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy defines medical necessity criteria, dosing, continuation, and exclusions for intravenous CGRP monoclonal antibody therapy (Vyepti/eptinezumab) for migraine prophylaxis in adult members covered by Blue Cross of Idaho benefit plans.

Policy Summary

PayerBluecross Idaho

PolicyIntravenous Monoclonal Antibody Therapy for Migraine Headache

Policy CodePolicy MP 5.01.529

Change TypeAdministrative update — no material clinical or coverage changes

Effective DateApr 30, 2026

Last ReviewApr 30, 2026

Next Review DateApr 30, 2026

Key ActionObtain prior authorization documenting diagnosis, baseline monthly migraine days, and prior preventive therapy trials (typically 2–4 classes) before initiating IV eptinezumab.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

100 mgrecommended IV dosage

q3 monthsrecommended dosing interval

300 mgdose escalation option

>=4/moepisodic migraine threshold

4+trial MMD threshold

≥5000patients in pivotal trials

Coverage Criteria for Intravenous CGRP Monoclonal Antibody Therapy

Initial Therapy

Covered when ALL of the following are met:

Diagnosis: Individual has a diagnosis of episodic migraine (≥4 and <15 migraine days/month averaged over the prior 3 months) or chronic migraine (≥15 headache days/month for >3 months with ≥8 days/month having migraine features)see definitions

Based on ICHD-3 definitions referenced in policy

Indication: IV CGRP therapy is being used for migraine prophylaxis

IV route (eptinezumab) administered in a healthcare setting

Prior oral preventive trials: Inadequate response to at least a 2-month trial at target/usual effective dose or intolerance to two agents for migraine prophylaxis (at least one agent in any two of the listed classes: antidepressants [amitriptyline, venlafaxine, nortriptyline, duloxetine]; beta blockers [metoprolol, propranolol, timolol, nadolol, atenolol, nebivolol]; calcium channel blocker [verapamil]; antiepileptic agents [valproate/divalproex, topiramate, gabapentin]; Botox for chronic migraine)

Policy Summary

PayerBluecross Idaho

PolicyIntravenous Monoclonal Antibody Therapy for Migraine Headache

Policy CodePolicy MP 5.01.529

Change TypeAdministrative update — no material clinical or coverage changes

Effective DateApr 30, 2026

Last ReviewApr 30, 2026

Next Review DateApr 30, 2026

Key ActionObtain prior authorization documenting diagnosis, baseline monthly migraine days, and prior preventive therapy trials (typically 2–4 classes) before initiating IV eptinezumab.

SourceLink

On This Page

2 agents or 2-month trial

Policy enumerates classes and agents

Prior CGRP therapy (when pharmacy benefit applies): Inadequate response or intolerance to two (2) of the following per the individual's pharmacy benefit when applicable: Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), Qulipta (atogepant)2 agents

Only applicable for membership with Blue Cross of Idaho pharmacy benefits

Concurrent botulinum toxin use: If IV CGRP therapy will be used concurrently (not as a switch) with botulinum toxin, member must have had reduction in migraine days or severe migraine days with the initial agent AND continue to have a significant number of migraine days/severe days requiring additional preventive therapy

Applies when combined therapy prescribed

Continuation Therapy

Continuation requests considered medically necessary when ALL of the following are met:

Prior approval met: Coverage criteria for initiation of IV CGRP therapy have been previously met

Clinical response - frequency: Individual has a reduction in the overall number of migraine days or in the number of severe migraine days per month compared with baseline

Compare to baseline documentation

Clinical benefit measures: Individual has obtained clinically significant benefit as deemed by the patient or prescriber, demonstrated by any one of: 50% reduction in frequency of headache/migraine days; significant decrease in attack duration; significant decrease in attack severity; improved response to acute treatment; reduction in migraine-related disability and improved functioning; improvement in health-related quality of lifeany 1 of listed

AHS 2021 referenced for acceptable benefit measures

Concurrent botulinum toxin continuation: If using concurrently with botulinum toxin, individual must have further reduction in migraine days or severe days compared to monotherapy with the initial agent

Applies to continuing combined therapy

Initial therapy / Trial-based eligibility

Covered when clinical trial–like criteria are met (as presented in this evidence review):

Population: Patient has episodic migraine and is eligible for standard pharmacologic preventative therapyepisodic migraine

Defines population of interest per policy clinical context

Baseline frequency: Baseline monthly migraine days documented as >=4>=4 MMD (many pivotal trials used 4–14 MMD)

Most pivotal RCTs required ≥4 MMD

Prior preventive therapy documentation: Documentation of prior preventive therapy attempts or intolerance may be required; trials varied and excluded patients who had failed ≥2–3 classes in many pivotal trials while some allowed 0–2 prior failuresvariable (0–3 prior preventive failures)

Eligibility and expectations vary by trial; coverage may require failure or intolerance of oral prophylactics

Evidence-based population and endpoints

Evidence from randomized controlled trials supports efficacy of CGRP-targeted monoclonal antibodies in adults with episodic migraine meeting typical trial inclusion criteria.

RCT population characteristics: Adults enrolled in RCTs generally had ≥4 monthly migraine days (upper limits varied by trial, commonly 14–16) with variable prior preventive medication use; many trials excluded patients who had failed ≥2–3 classes of preventive treatments>=4 monthly migraine days

Derived from multiple pivotal RCTs summarized in the evidence review

Initial coverage for episodic migraine not responsive to standard preventive therapy

Covered when ALL of the following are met (policy focus and population):

Population and indication: Individual has episodic migraine not responsive to standard pharmacologic preventive therapy

Policy focuses on episodic migraine not responsive to standard therapy

Therapy class: Therapy is a monoclonal antibody targeting the CGRP molecule or the CGRP receptor (examples: erenumab, eptinezumab, fremanezumab, galcanezumab); IV route applies to eptinezumab

Includes IV administration for eptinezumab per document

Evidence and applicability

Clinical evidence considerations influencing coverage decisions:

Magnitude of benefit: Placebo-controlled RCTs show mean reductions of approximately 1–2 monthly migraine days and improved responder rates for several agents; network meta-analysis found no clear superiority versus some oral preventive therapies for certain mAbs

Limited long-term data and lack of head-to-head trials for eptinezumab vs oral therapies noted

Generalizability limits: Trials enrolled predominantly White, female populations and often excluded children, older adults, and pregnant or lactating women; applicability to patients who have tried >3 preventive therapies or who have significant comorbidities is limited

May affect coverage for populations outside trial demographics

Initial therapy / Eligible population

Covered when ALL of the following are met:

Population and prior therapy: Patient has episodic migraine not responsive to standard pharmacologic preventive therapy AND documented prior failure of commonly 2 to 4 classes of preventive medicationsprior failures = 2 to 4 classes

Trials (LIBERTY, FOCUS, CONQUER, DELIVER) enrolled patients with documented failures of 2–4 classes

Evidence requirements

Supportive efficacy evidence for covered use:

Evidence of benefit: Randomized trials and systematic reviews demonstrated reductions in mean monthly migraine days, higher ≥50% and ≥75% responder rates, and improved patient-reported quality-of-life measures for CGRP mAbs; sustained benefit observed in open-label extensionsclinically meaningful reductions over 12–24 weeks

PROMISE and DELIVER trials and extensions reported responder and QOL improvements

Initial therapy / coverage criteria

Covered when ALL of the following are met (context from evidence review):

Eligibility: Patient has episodic migraine who failed 2–4 other preventive treatments OR patient has chronic migraine who is eligible for standard pharmacologic preventative therapyfailure of 2–4 preventive treatments

episodic and chronic contexts described; trials support these populations

Baseline and measurement: Baseline monthly migraine days documented and a planned assessment of change (monthly migraine days and responder rates) typically at ~12 weeksassessment at ~12 weeks

Responder definitions include ≥50% decrease

Administration documentation: Route of administration specified (IV agents administered in healthcare setting; SC agents may be self-administered) with dose and schedule documentedadministration route documented

Eptinezumab studied as IV infusion every 12 weeks at 100 mg and 300 mg

Continuation therapy

Continuation or duration considerations (evidence-supported):

Durability and follow-up: Continue therapy when clinically meaningful reduction in monthly migraine days and responder benefit are sustained; extension data show sustained effects to 24 weeks or longer for some agents (eptinezumab, fremanezumab)clinical benefit sustained

PROMISE-2 and fremanezumab 52-week extension data support durability

Applicability / Evidence limitations

Evidence-based applicability considerations and limitations for use of CGRP mAbs (including IV eptinezumab) in chronic migraine patients who are eligible for standard pharmacologic preventative therapy:

Applicability and evidence caveats: Use may be considered when patient has chronic migraine with documented baseline migraine days and prior preventive treatment history; RCTs show modest incremental reductions (up to ~2.6 fewer monthly migraine days) and higher ≥50% responder rates for eptinezumab and other CGRP mAbs, but generalizability is limited for patients who have failed >3 preventive therapies, have major comorbidities, are pediatric, older adults, or pregnant/lactating; long-term safety beyond 1–2 years is uncertainsee notes

Trials often restricted to patients with ≤2–3 prior preventive failures and short primary follow-up; cardiovascular and other long-term AEs remain evidence gaps

Initial coverage criteria for refractory chronic migraine

Covered when ALL of the following are met:

Eligibility for refractory chronic migraine: Patient has chronic migraine (≥4 migraine days/month as enrolled in trials) AND documented failure of 2 to 4 classes of migraine preventive medications within the past 10 years due to lack of efficacy or tolerability>=4 migraine days/month; failure of 2-4 classes

Derived from inclusion criteria of refractory trials (LIBERTY, FOCUS, CONQUER, DELIVER)

Episodic Cluster Headache — Galcanezumab

Covered when ALL of the following are met:

Episodic cluster headache coverage criteria: Patient meets ICHD diagnostic criteria for episodic cluster headache with documented baseline attack frequency (e.g., ≥4 attacks in a 7-day baseline) AND has failed or has contraindication/intolerance to standard oral prophylactic agents (e.g., verapamil, lithium) or standard preventive therapysee node text

Based on RCT showing greater early reduction in weekly attacks and higher ≥50% responder rates at week 3 for galcanezumab vs placebo; consider limited long-term data and spontaneous remission course

Chronic Migraine — CGRP mAbs

Covered when ALL of the following are met:

Chronic migraine coverage context: Patient has chronic migraine (trials referenced patients with ≥4 migraine days/month) AND has failed 2–4 other preventive treatments; clinician documents prior preventive therapy failures and conducts a benefit–risk assessment considering modest trial benefits versus uncertainties about durability and long-term safetyfailed 2-4 prior preventives

Pivotal trials reported mean effects of ~2–2.6 fewer migraine days/month for eptinezumab and up to ~3.8 days for some mAbs in subgroups

Treatment with intravenous (IV) CGRP monoclonal antibody therapy is limited to the indications and criteria described elsewhere in this policy. IV CGRP therapy is considered investigational for all other uses, including use for acute migraine treatment.

Small-molecule CGRP receptor antagonists ("gepants") and rimegepant when used as an oral agent for prophylaxis or acute therapy are not within the scope of this monoclonal antibody policy. Gepants and similar oral CGRP-targeting agents are therefore not addressed as covered therapies under this IV monoclonal antibody evidence review.

Many pivotal randomized controlled trials excluded patients with prior failure of multiple preventive medication classes. Key trial exclusion criteria commonly included failure of ≥2 classes of preventive treatments, and some trials (for example EVOLVE-1/2) specified failure of ≥3 classes or otherwise restricted prior preventive use as detailed in trial enrollment summaries.

No additional explicit coverage exclusions are stated in the cited excerpt.

The provided excerpt does not list any explicit coverage exclusions beyond those already noted elsewhere in the policy text.

Within the extracted material there are no additional explicit coverage exclusions identified.

This excerpt does not contain explicit coverage exclusion statements beyond other sections of the document.

No specific coverage exclusions are described in this portion of the document.

The pivotal randomized trials largely excluded certain populations; consequently, evidence is lacking for children, older adults, and women during pregnancy and lactation because these groups were not enrolled in the pivotal RCTs and generalizability to these populations is therefore limited.

Use of IV CGRP monoclonal antibodies outside the studied population — for example for primary prevention or for headache types not represented in the trials — is not supported by the trial evidence summarized in this review and is therefore outside the populations addressed by the policy.

The evidence base has limited generalizability: trials often enrolled predominantly White, female adults and had relatively short follow-up. As a result, applicability to children, older adults, and pregnant or lactating women is limited, and long-term safety beyond 1–2 years remains uncertain.

The trial populations and relevance limitations suggest evidence may not apply to patients who have tried more than three prior preventive therapies, patients with substantial comorbidities, pediatric patients, older adults, and women during pregnancy or lactation.

Generalizability is limited for pediatric patients, older adults, and pregnant or lactating women, and trial follow-up periods are generally too short to fully characterize long-term safety beyond one to two years.

Major cardiovascular events and certain vascular conditions were exclusion criteria in some trials. Specifically, trials excluded participants with recent major cardiovascular events, history of stroke or intracranial hemorrhage, vasospastic angina, peripheral vascular disease, Raynaud's disease, and certain thromboembolic events; similar considerations may be applied when assessing eligibility.

The policy considers concomitant use of an IV CGRP monoclonal antibody together with another prophylactic CGRP agent (e.g., Aimovig, Ajovy, Emgality, Qulipta, or prophylactic Nurtec ODT) to be not medically necessary and such combination therapy would trigger denial per the policy statement.

The document presents comparisons of CGRP monoclonal antibodies to placebo and to oral prophylactics in network meta-analyses, but it does not explicitly state a general 'not medically necessary' declaration for all uses; instead it interprets evidence and notes limited incremental benefit in some populations.

No explicit 'not medically necessary' statements are present in the extracted text beyond specific combination-use prohibitions and population caveats described elsewhere.

The provided excerpt does not contain additional explicit 'not medically necessary' policy-language aside from combination therapy and population limitations.

No explicit 'not medically necessary' statements are contained in this particular extract beyond those already cited in other sections.

This excerpt does not include explicit not-medically-necessary statements.

No explicit not-medically-necessary statements appear in this portion of the document.

Use of CGRP monoclonal antibodies in populations not represented in trials — including pediatric patients, pregnant or lactating women, and many older adults — may be considered not medically necessary or require additional justification due to lack of supporting evidence and limited long-term safety data.

Initiating CGRP monoclonal antibody therapy before attempting or documenting adequate supportive care or standard preventive therapies is inconsistent with the populations enrolled in most trials and the policy's coverage rationale; such first-line use is not aligned with trial evidence.

Use in populations lacking supporting evidence or where long-term safety is the primary concern (for example pregnant or lactating women, children, and some older adults) should be approached cautiously and may require additional justification given the limited data on durability and rare or late adverse events.

The document frames some recommendations as interpretations of the evidence rather than absolute denials: network meta-analysis showed no statistical superiority of several CGRP mAbs versus some oral therapies and long-term data are limited; therefore the incremental benefit of CGRP mAbs for patients who remain eligible for and are responding to standard oral preventive therapy is uncertain.

Use of CGRP monoclonal antibodies in patients who are eligible for standard oral pharmacologic preventive therapy and have not yet tried those therapies is of uncertain incremental benefit, given the lack of head-to-head superiority in network analyses and limited long-term evidence.

For episodic cluster headache, using a CGRP mAb such as galcanezumab as a first-line therapy when standard oral prophylactic agents (e.g., verapamil, lithium) have not been tried or are not contraindicated is not supported by head-to-head data and limited long-term evidence; thus first-line use in that setting may be considered not medically necessary.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior authorization: required and documentation elements

Prior authorization is required for IV CGRP therapy; the request should document the diagnosis (episodic or chronic migraine), prior medication trials including inadequate response or intolerance to at least a 2‑month trial at target/usual dose or intolerance to two agents (at least one agent in any two specified classes), prior use or contraindication to listed oral prophylactics, and prior use/intolerance to two specified CGRP agents when applicable under the member’s pharmacy benefit.

Document diagnosis per policy definitions (episodic or chronic migraine).
Document prior preventive medication trials: inadequate response to ≥2 months at target/usual dose or intolerance to two agents (one agent in any two classes listed).
If pharmacy benefit applies, document inadequate response or intolerance to two of: Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), or Qulipta (atogepant).
Specify planned agent and route (IV vs SC) and dosing schedule.

Documentation Required

Document prior therapy history and baseline MMD

Provide prior preventive therapy history and baseline monthly migraine days (MMD) over the prior 3‑month period; trials and the policy expect documentation of prior failures or intolerance to specified oral preventive therapies as relevant to eligibility.

Baseline MMD (average over prior 3 months) — many trials required ≥4 MMD.
Record prior trials/intolerances of oral prophylactics (antidepressants, beta‑blockers, verapamil, antiepileptics) with durations and outcomes.

Documentation Required

Prior preventive trials and baseline severity must be documented

Expect reviewers to verify number and classes of prior preventive medication trials and baseline migraine frequency consistent with RCT entry criteria (typically ≥4 MMD for episodic migraine).

List classes and agents tried and reasons for discontinuation (lack of efficacy or intolerance).
Confirm baseline monthly migraine days consistent with trial criteria (commonly 4–14 MMD).

Note

No PA details in some excerpts — refer to policy prior auth section

Some source sections do not state explicit prior authorization steps or billing codes; however, the policy overall includes PA requirements elsewhere — do not assume absence of PA from isolated excerpts.

Study-result–only excerpts may omit administrative PA details; rely on the policy's Prior Authorization section for requirements.

Note

Prior authorization not specified in study-result excerpts

Portions of the document provided contain only trial results and do not specify prior authorization; use the policy’s authorization statements (see Prior Authorization requirements) rather than the isolated study text for PA determination.

Clinical trial results excerpts (efficacy/safety data) do not replace policy PA requirements.

Note

No PA code list in these excerpts

The excerpted study data do not list mandatory PA codes or explicit administrative PA steps; confirm PA requirements using the policy's Prior Authorization module.

Do not infer billing/coding decisions solely from trial data sections.

Note

Trial results present but PA code requirements not stated here

Clinical trial results and dosing comparisons appear in other sections but do not by themselves define prior authorization code requirements — follow the policy's PA instructions for administrative coding and submission.

Use the policy Prior Authorization and Coding sections for submission requirements.

Prior Authorization

Evidence present in excerpt — include with PA but PA codes not listed here

The document includes trial summaries (EVOLVE‑2, PROMISE‑1, etc.) supporting clinical use but does not list explicit PA code lists in those evidence sections; include trial evidence when submitting PA but follow the policy's PA checklist.

Attach relevant trial identifiers/outcomes (e.g., PROMISE‑1, EVOLVE‑2) as supporting evidence when applicable.

Prior Authorization

PA expected for episodic migraine not responsive to standard therapy

For episodic migraine not responsive to standard pharmacologic preventive therapy, prior authorization is anticipated; the policy frames CGRP mAbs as options for this population and requires documentation of that indication.

Document that the patient has episodic migraine not responsive to standard preventive therapy per policy definitions.

Prior Authorization

PA must confirm diagnosis, prior preventive failures, and planned route

Prior authorization should verify diagnosis of episodic migraine and prior preventive treatment failures (commonly 2–4 classes) and intended agent/route (IV eptinezumab or other CGRP mAb).

Confirm diagnosis per ICHD‑3/Policy definition and list prior preventive therapy failures (2–4 classes when applicable).
Specify intended agent and route (e.g., eptinezumab IV vs subcutaneous mAb).

Prior Authorization

PA: confirm baseline frequency, prior failures, and planned dosing/assessment

Prior authorization requests should confirm baseline migraine frequency, prior preventive therapy failures or intolerance, and the planned dosing/route with outcomes to be measured at ~12 weeks.

Provide baseline MMD and planned outcome assessment timing (typically 12 weeks).
List prior preventive therapies tried and reasons for discontinuation.

Prior Authorization

PA: eptinezumab (IV) dosing and infusion documentation

When requesting authorization for eptinezumab (IV), include the intended IV dose and infusion schedule (studied as 100 mg and 300 mg IV every 3 months) and document prior preventive therapy history and baseline migraine frequency.

State planned IV dose (100 mg every 3 months is standard; 300 mg may be used in some patients) and infusion intervals.
Document infusion will be administered in a healthcare setting and include administration details.

Prior Authorization

PA: chronic migraine — confirm chronic diagnosis and 2–4 prior preventive failures

For refractory chronic migraine, prior authorization should confirm the diagnosis (chronic migraine, ≥4 migraine days/month as referenced) and documented failure of 2–4 classes of preventive medications.

Provide documentation of failure of 2–4 preventive classes within the past 10 years (lack of efficacy or intolerance).
Include baseline MMD and outcome measures.

Prior Authorization

PA expectation: document failure/intolerance to standard oral preventives

CGRP mAbs are positioned as options for patients who have failed standard preventive therapies or have contraindications to them; prior authorization commonly expects documentation of prior oral preventive therapy failure or intolerance.

Document trials of standard oral preventive therapies and reasons for failure/intolerance when applicable.

Step Therapy

Step therapy: require ≥2‑month trial or intolerance to two agents

Step therapy in the policy context requires inadequate response to at least a 2‑month trial at target/usual dose or intolerance to two agents across specified classes; document trial duration and dose when applicable.

Provide dates, durations (≥2 months at target/usual dose), and outcome of prior trials.
If claiming intolerance, document adverse effects leading to discontinuation.

Step Therapy

Stepwise use: CGRP mAbs after or as alternatives to oral prophylactics

CGRP monoclonal antibodies are generally considered after or as alternatives to standard oral preventive therapies; some trials excluded patients who had failed multiple classes, supporting stepwise consideration.

If patient is eligible for standard oral preventives, document why CGRP mAb is being considered (failure/intolerance/contraindication).

Step Therapy

Step therapy context: RCTs commonly required ≥2 prior preventive failures

Many RCTs required prior preventive treatment failure (commonly ≥2 classes); include this trial‑based context when seeking authorization to support stepwise use of anti‑CGRP therapy.

Cite relevant trial criteria (e.g., LIBERTY, FOCUS, CONQUER) showing requirement of 2–4 prior preventive failures when applicable.

Note

No step therapy details in these excerpts — follow policy Step Therapy section

The provided excerpts contain no additional step therapy sequencing requirements; nonetheless, the policy elsewhere defines step therapy expectations — follow the policy's Step Therapy statements for administrative steps.

When no step therapy specifics are in an excerpt, rely on the policy's Step Therapy section for required documentation.

Documentation Required

Required clinical documentation for authorization

Required clinical documentation for PA should include diagnosis (episodic or chronic migraine), migraine/headache day frequency over the previous 3 months, prior trials and responses or intolerances to specified prophylactic agents, and concurrent botulinum toxin response data when applicable.

Diagnosis per policy definitions and baseline MMD over prior 3 months.
Prior preventive medication history with durations, doses, and outcomes.
If on botulinum toxin concurrently, document prior response and ongoing need for additional therapy.

Documentation Required

Document baseline and outcome measures (MMD, responder rates, QOL instruments)

Document outcome measures and baseline monthly migraine days (MMD) and responder status (≥50%/75%/100%); use instruments such as MIDAS, HIT‑6, MPFID and plan assessment over 3–12 months to demonstrate response.

Record baseline and follow‑up MMD and responder percentages at ~12 weeks.
Include validated outcome measures (MIDAS, HIT‑6, MPFID) where available.

Documentation Required

Provide prior preventive medication history with outcomes

Provide prior preventive medication history showing trials and treatment failures; trial reporting is commonly used in RCTs and should be available to support coverage decisions.

List oral and injectable preventive agents tried with dates and documented lack of efficacy or intolerance.
When pharmacy benefit applies, include prior CGRP agent trials (Aimovig, Ajovy, Emgality, Qulipta) if claimed.

Documentation Required

Attach relevant trial evidence to support medical necessity

The document includes trial outcome data that could support medical necessity (trial identifiers and outcome summaries); attach relevant trial evidence (e.g., PROMISE‑1, PROMISE‑2) when submitting authorization but follow the policy’s required documentation checklist.

Include trial identifiers (e.g., PROMISE‑1 n=665) and reported mean MMD changes if used as supporting evidence.

Documentation Required

Documentation for IV administration: route, dose, infusion setting

For IV administration (eptinezumab), document that infusion will be given by a healthcare provider in a healthcare setting and include route, dose, and infusion details in the submission.

Specify IV infusion dose (100 mg or 300 mg) and schedule (every 3 months) and where the infusion will be administered.
Include any administration notes (e.g., observation, infusion reactions) if relevant.

Documentation Required

Confirm episodic migraine diagnosis and prior preventive failures in PA

Document that the patient has episodic migraine and prior failure of preventive therapies (commonly 2–4 classes) and specify route of administration (IV vs SC) when requesting authorization.

State whether patient meets episodic or chronic migraine definition per policy.
List prior preventive classes failed (2–4) with dates and reasons.

Documentation Required

PA documentation: baseline MMD, prior treatments, and planned outcome assessment

Documentation should include baseline monthly migraine days, prior preventive treatments tried and failed or not tolerated, and outcome measures (change in MMD and responder rate) typically assessed at 12 weeks.

Baseline MMD, planned assessment timepoint (commonly 12 weeks), and prior treatment history.
Report responder outcomes (≥50% reduction) if available from clinical follow‑up.

Documentation Required

Suggested documentation: baseline MMD and prior preventive medication history

Trials generally required baseline documentation of monthly migraine days and prior preventive medication history (PROMISE‑2 required stable prophylactic meds for ≥3 months); reviewers should document baseline MMD and prior preventive therapy attempts to support medical necessity.

If a concurrent stable prophylactic medication is used, note stability duration (e.g., ≥3 months in PROMISE‑2).

Denial Risk

Combination CGRP prophylaxis is NOT medically necessary

Use of IV CGRP therapy in combination with another prophylactic CGRP agent (Aimovig, Ajovy, Emgality, Qulipta, or prophylactic Nurtec ODT) is considered NOT medically necessary and will trigger denial.

Do not authorize combination prophylactic CGRP agents; requests for combined CGRP prophylaxis should be denied.

Denial Risk

Prior treatment history can affect eligibility and authorization

Trials excluded patients who had failed ≥2 or 3 classes of preventive treatments in many pivotal RCTs; prior treatment history may therefore affect eligibility and should be documented to avoid denial.

If patient has failed >3 prior preventive therapies, note that generalizability is limited and reviewers may request additional justification.

Denial Risk

Trial‑based exclusion risks may influence authorization

Key trial exclusion criteria often included failure of ≥2 classes of preventive treatments and recent use of devices or certain injectable therapies; presence of trial‑exclusion conditions may affect authorization determinations.

List any exclusionary comorbidities (e.g., recent CV events) or recent use of neuromodulation/devices that mirror trial exclusions.

Denial Risk

Evidence/generalizability concerns that may trigger review

Lack of evidence of superiority versus oral preventive therapies and limited generalizability (e.g., excluded populations) may prompt utilization review to request additional justification or to restrict coverage for patients outside trial populations.

Prepare justification for use in populations not well represented in trials (children, older adults, pregnant/lactating women, patients with multiple comorbidities).

Denial Risk

Use outside studied population risks denial

Use of CGRP mAbs outside the studied population (e.g., not episodic migraine not responsive to standard therapy) or without documented prior treatment failure may be outside the policy's population of interest and risk denial.

Ensure indication aligns with policy (episodic migraine not responsive to standard pharmacologic preventive therapy) to reduce denial risk.

Denial Risk

Safety and generalizability concerns may trigger additional review

Concerns about long‑term safety, durability of benefit, and limited generalizability (children, older adults, pregnancy/lactation) may lead to requests for additional justification or denial for populations without supporting evidence.

Anticipate reviewer questions regarding long‑term safety and cardiovascular risk; provide supporting rationale if treating patients in excluded groups.

Denial Risk

Evidence limitations that may affect authorization decisions

Generalisability limitations and limited long‑term data (e.g., patients who tried >3 preventive therapies or with significant comorbidities) may be cited during utilization review to question applicability for authorization.

Document clinical rationale when patient has unique characteristics outside trial populations.

Denial Risk

Absence of documented prior failures or baseline frequency may cause denial

Lack of documented prior treatment failure or not meeting chronic migraine criteria (≥4 migraine days/month referenced in trials) could trigger denial; ensure documentation demonstrates prior failures and baseline frequency.

If claiming chronic migraine, document ≥4 migraine days/month and prior preventive treatment failures (2–4 classes) as applicable.

Denial Risk

Evidence gaps (CV comorbidity, pregnancy, pediatrics) may trigger denial

Limited generalizability for patients with cardiovascular comorbidities, children, pregnant women, and short‑term trials may prompt denial or restriction without strong justification; supply comorbidity‑specific rationale if applicable.

Provide cardiovascular history and rationale if treating patients with CV comorbidities given CGRP's physiological roles.

Note

Coding and Key Clinical Metrics

Coding table referencedmixed

No codes listed

Relevant drugs discussed (not billing codes)NDC|mixed

eptinezumab (drug discussed)

Eptinezumab referenced (100 mg and 300 mg doses) in PROMISE-1 and other trial data

Referenced treatment modalities (no billing codes listed)mixed

not provided

The document references IV infusion of eptinezumab every 3 months (100 mg, 300 mg) but does not list specific CPT/HCPCS/NDC codes in this section.

Monthly migraine days (trial eligibility) — ≥4 MMD

Trial enrollment threshold>=4 monthly migraine days (commonly used as lower bound in pivotal trials)

Typical trial rangeMost episodic migraine RCTs enrolled patients with ~4–14 monthly migraine days

Upper-range exceptionsSome trials allowed up to 15–16 monthly migraine days or included chronic migraine (>=15 headache days/month)

Monthly migraine days for trial inclusion — common limits

Common inclusion window>=4 and <=14 monthly migraine days in most episodic migraine RCTs

Wider trial limitsSome trials enrolled up to <=15 or <=16 monthly migraine days (trial-specific)

Population noteRange reflects episodic migraine definitions used across multiple pivotal trials

Responder definition

Responder (primary/clinically meaningful)>=50% reduction in monthly migraine days

Other responder thresholds reported>=75% and 100% decreases also reported as secondary responder outcomes

Assessment timingResponder rates typically assessed at ~12 weeks (primary trial interval)

Monthly migraine days — common eligibility threshold

Eligibility lower bound used>=4 monthly migraine days used as an entry threshold in several trials

RationaleReflects MMD baseline documentation required for enrollment and coverage considerations

Documentation implicationBaseline MMD over prior months should be recorded to confirm eligibility

Definitions, Background and Trial Context

Background: Migraine is a recurrent headache disorder classified by frequency into episodic and chronic forms; CGRP plays a role in migraine pathophysiology and is the target of monoclonal antibody therapies. Vyepti (eptinezumab) is the only IV-administered FDA-approved CGRP monoclonal antibody for migraine prophylaxis in adults, and IV administration requires healthcare-provider delivery in a healthcare setting.

Episodic migraine

Episodic migraine definitionAt least 4 and fewer than 15 migraine days per month and fewer than 15 headache days per month on average during the previous 3-month period.

Time window for diagnosisAverage over the previous 3 months

Classification useUsed to distinguish episodic from chronic migraine for coverage and trial eligibility

Chronic migraine

Chronic migraine definitionHeadache occurring on 15 or more days per month for more than 3 months, which on at least 8 days per month has features of a migraine headache (ICHD-3).

Duration requirement>3 months of headache frequency to meet chronic definition

Migraine-day requirement within headachesAt least 8 migraine-feature days per month among the >=15 headache days

CGRP monoclonal antibodies (mAbs)

DefinitionHumanized monoclonal antibodies that bind to the calcitonin gene-related peptide (CGRP) receptor (e.g., erenumab) or the CGRP molecule (e.g., eptinezumab, fremanezumab, galcanezumab).

Administration routesAvailable as subcutaneous (self-administered) or intravenous (administered in healthcare setting) formulations

IndicationsApproved for preventive treatment of migraine in adults (specific agents and indications vary by product)

MMD — Monthly Migraine Days

MMD (term)Monthly Migraine Days: the average number of days with onset or continuation of a migraine headache; primary outcome in prevention trials.

Use in trialsMMD is typically the principal endpoint for efficacy (change from baseline reported)

Assessment periodMeasured over monthly intervals and compared across treatment periods (commonly 12 weeks)

Episodic migraine (trial definitions)

Episodic migraine in RCTsIn included RCTs episodic migraine was typically defined as adults with approximately >=4 to <=14 migraine headache days per month (some trials up to <=16).

Trial variabilityUpper MMD limit varied by trial (e.g., some HALO EM included <=16 MMD)

Implication for enrollmentInvestigators used these MMD ranges to select episodic migraine populations for pivotal efficacy trials

CGRP monoclonal antibodies (mAbs) — agents and dosing

Examples of agents studiedErenumab, fremanezumab, galcanezumab, and eptinezumab were evaluated in randomized trials

Dosing examplesDoses studied included erenumab 70/140 mg, fremanezumab 225 mg monthly or 675 mg quarterly, galcanezumab 120/240 mg, and eptinezumab IV 100 mg/300 mg every 3 months

RoutesAgents administered subcutaneously (most) or intravenously (eptinezumab) in trials

Revision History

2026-04-30policy_reviewLatest

Annual review and policy replacement; effective date 04/30/2026 with continued coverage criteria for IV CGRP therapy (Vyepti/eptinezumab)

2025-04-01dosing_update

Policy statement updated with additional dosing information; Blue Cross of Idaho adopted changes effective 04/01/2025

2024-02-29policy_adoption

New policy added to Prescription Drug section and adopted by Blue Cross of Idaho, effective 06/01/2024